For the Inventor, By the Inventor

Enter inventor name

Headington, United Kingdom

Steven John Durrant

USPTO Granted Patents = 70 (Patent Applications = 29)

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 26 (Patent Applications = 38)

Average Co-Inventor Count = 6.9

ph-index = 18

Forward Citations = 698(Granted Patents)

Forward Citations (Not Self Cited) = 451(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Abingdon, Oxfordshire, GB (2010)
Oxfordshire, GB (2012)
Abingdon, GB (2010 - 2024)
Headington, GB (2023 - 2024)

Company Filing History:

69 out of 1,149

Vertex Pharmaceuticals, Inc.

Merck Patent Gmbh

1 out of 832,718

Other

patents

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Sodium Channels

ATR Kinase Inhibitors

GCN2 Inhibitors

Tetrahydrofurans

Pyrazines

Pyrimidine Derivatives

Protein Kinase Inhibitors

Thiophene-Carboxamides

Azaindazoles

Substituted Pyrazin-2-Amines

Pyrrolo[2,3-B]Pyrazines

Hydroxyalkyl Carboxamides

70 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12258333 - N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels (2025-03-25),

2. 12247021 - Substituted tetrahydrofurans as modulators of sodium channels (2025-03-11),

3. 12187731 - Compounds useful as inhibitors of ATR kinase (2025-01-07),

4. 12084438 - GCN2 inhibitors and uses thereof (2024-09-10),

5. 11919887 - Substituted tetrahydrofurans as modulators of sodium channels (2024-03-05),

6. 11834441 - Substituted tetrahydrofurans as modulators of sodium channels (2023-12-05),

7. 11827627 - N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels (2023-11-28),

8. 11370798 - Compounds useful as inhibitors of ATR kinase (2022-06-28),

9. 11117900 - Compounds useful as inhibitors of ATR kinase (2021-09-14),

10. 10988477 - GCN2 inhibitors and uses thereof (2021-04-27),

11. 10961232 - Substituted pyrazines as ATR kinase inhibitors (2021-03-30),

12. 10822331 - Processes for preparing ATR inhibitors (2020-11-03),

13. 10793563 - GCN2 inhibitors and uses thereof (2020-10-06),

14. 10787452 - Compounds useful as inhibitors of ATR kinase (2020-09-29),

15. 10479784 - Substituted pyrazin-2-amines as inhibitors of ATR kinase (2019-11-19),

Title: Exploring the Innovations of Inventor Steven John Durrant

Introduction:

Steven John Durrant, a prolific inventor hailing from Headington, GB, has made significant contributions to the field of pharmaceuticals with an impressive portfolio of 66 patents.

Latest Patents:

Among his recent patents is the groundbreaking invention titled "Substituted tetrahydrofurans as modulators of sodium channels." These compounds and their pharmaceutically acceptable salts have showcased potential as inhibitors of sodium channels, offering novel treatment avenues for various disorders, particularly in the realm of pain management.

Career Highlights:

Throughout his career, Steven John Durrant has been associated with renowned companies such as Vertex Pharmaceuticals, Inc. and Merck Patent GmbH, where he has honed his expertise in pharmaceutical innovation and patent development.

Collaborations:

In his professional journey, Steven has collaborated with esteemed colleagues like Jean-Damien Charrier and Ronald Marcellus Knegtel, fostering a culture of innovation and excellence within the pharmaceutical research landscape.

Conclusion:

Inventor Steven John Durrant's relentless pursuit of innovation and pioneering spirit in the field of pharmaceuticals underscore his commitment to advancing healthcare solutions. His patents stand as a testament to his ingenuity and dedication to improving the quality of life for individuals worldwide.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…